Bonjour, Vous écrivez : « / le vaccin disponible aux U.S n’a pas encore été expérimenté, celà demanderait au moins 1 an d’expérimentation au préalable. De plus les laboratoires pharmaceutiques ne sont pas intéressés pour le développer puisque cette maladie tropicale ne touche que les pays pauvres du sud (pas d’intérêt commercial), La Réunion étant une exception dans la zone. »

A l’adresse ci dessous, vous trouverez une mise à jour des informations par Robert Edelman qui a réalisé les essais de phase II du vaccin TSI-GSD-218.

http://www.promedmail.org/pls/pm/pm?an=20060219.0544

comme l’article est long, je transcrit ci-dessous un paragraphe fort interessant :

"(...)The vaccine is managed under IND [Investigative New Drug protocol] by the United States Army Medical Research Acquisition Activity, Fort Detrick, Frederick, MD USA. I do not think the vaccine was tested further after our trial.

I have put the French Health Authorities in contact with the U.S. Army.

—  Robert Edelman, MD, FACP Professor of Medicine and Pediatrics University of Maryland School of Medicine Associate Director for Clinical Research Center for Vaccine Development 685 West Baltimore Street, Room 480 Baltimore, Maryland 21201 <[email protected]>(...)

ci dessous, le résumé de l’article qui relate l’essai du vaccin tel qu’il apparait dans PUBMED

SO - Am J Trop Med Hyg. 2000 Jun ;62(6):681-5.

TI - Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

AB - We conducted a phase II, randomized, double-blind, placebo-controlled, safety and immunogenicity study of a serially passaged, plaque-purified live chikungunya (CHIK) vaccine in 73 healthy adult volunteers. Fifty-nine volunteers were immunized one time subcutaneously with the CHIK vaccine and 14 were immunized with placebo (tissue culture fluid). Vaccinees were clinically evaluated intensively for one month, and had repeated blood draws for serological assays (50% plaque-reduction neutralization test) for one year. Except for transient arthralgia in five CHIK vaccinees, the number and severity of local and systemic reactions and abnormal laboratory tests after immunization were similar in CHIK vaccinees and placebo recipients. Fifty-seven (98%) of 58 evaluable CHIK vaccinees developed CHIK neutralizing antibody by day 28, and 85% of vaccinees remained seropositive at one year after immunization. No placebo recipients seroconverted. This promising live vaccine was safe, produced well-tolerated side effects, and was highly immunogenic.

AD - Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.

FAU - Edelman, R (...)

cordialement

Etonne